Sees FY26 Crysvita revenue in the range of $500M-$520M, reflecting growing underlying global demand partially offset by expected timing of ordering patterns in Brazil. Sees FY26 Dojolvi revenue in the range of $100M-$110M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- RARE Upcoming Earnings Report: What to Expect?
- Ultragenyx: UX111 Progress, Regulatory De-Risking, and Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating
- Ultragenyx Highlights New UX111 Data in FDA Resubmission
- Ultragenyx announces long-term data from studies evaluating UX111
- Ultragenyx: Advancing Rare Disease Pipeline, Key 2026–2027 Catalysts, and Path to Profitability Support Buy Rating